Recent clinical studies have shown that sodium glucose cotransporter 2 (SGLT2) inhibitors prevent cardiovascular events, particularly heart failure, in patients with type 2 diabetes mellitus (DM) (Zinman et al. The gene discussed is SLC5A2; the disease is heart failure.